Partnering
Terns to Stop Funding Metabolic Disease Trials Beyond 2025; Seeks Partners for Assets
Terns Pharmaceuticals; metabolic disease; clinical trials; pipeline strategy; partnering; oncology focus; TERN-601; TERN-701; GLP-1 agonists; CML
James Sabry Departs Roche After 14 Years, Returns to Biotech Industry
James Sabry, Roche, Genentech, Biotech, Partnering, Pharmaceutical Industry, Career Moves